Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Flutemetamol PET in Cardiac Amyloidosis
NCT03232632Phase 1Terminated
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Mar 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flutemetamol in cardiac amyloidosis, sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoints: Ratio Heart/Upper Mediastinum and Standardized Uptake Value Measures. Started Mar 2017; status: terminated.
02
Drugs
flutemetamol
03
Conditions
cardiac amyloidosis
Beyond the preview
Go deeper on NCT03232632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232632.